Comparison
Thymosin Alpha-1 vs TB-500
Side-by-side attributes from our library comparison data. Read each peptide leaf for dosing math, regulatory status, and citations.
Thymosin Alpha-1 vs. TB-500
| Attribute | Thymosin Alpha-1 | TB-500 |
|---|---|---|
| Mechanism | Immune modulation + thymic activation | Actin polymerization + cell migration |
| Primary Use | Immune support, infection, cancer adjuvant | Physical tissue healing, injury recovery |
| Evidence Quality | Human trials (37+ country approval) | Primarily preclinical |
| WADA Status | Prohibited (S4) | Prohibited (S0) |
| Dose Frequency | 900 mcg – 1.6 mg 2× weekly | 2–5 mg 2× weekly |
Verdict: Thymosin Alpha-1 targets immunity; TB-500 targets tissue healing. These peptides address completely different goals with minimal overlap - they are not competing options but complementary tools.